PEPGEN INC. (PEPG) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -76.24M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 52.80M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-76.24M | (m) | (m) | $52.80M | (m) | (m) |
| 2026-03-31 | $-81.23M | (m) | (m) | $58.67M | (m) | (m) |
| 2025-12-31 | $-93.61M | (m) | (m) | $71.04M | (m) | (m) |
| 2025-09-30 | $-98.25M | (m) | (m) | $76.15M | (m) | (m) |
| 2025-06-30 | $-102.77M | (m) | (m) | $80.45M | (m) | (m) |
| 2025-03-31 | $-109.26M | (m) | (m) | $87.12M | (m) | (m) |
| 2024-12-31 | $-97.74M | (m) | (m) | $76.48M | (m) | (m) |
| 2024-09-30 | $-94.20M | (m) | (m) | $73.82M | (m) | (m) |
| 2024-06-30 | $-95.81M | (m) | (m) | $76.64M | (m) | (m) |
| 2024-03-31 | $-86.53M | (m) | (m) | $68.50M | (m) | (m) |
| 2023-12-31 | $-84.77M | (m) | (m) | $68.13M | (m) | (m) |
| 2023-09-30 | $-81.17M | (m) | (m) | $64.99M | (m) | (m) |
| 2023-06-30 | $-75.94M | (m) | (m) | $60.42M | (m) | (m) |
| 2023-03-31 | $-72.44M | (m) | (m) | $57.73M | (m) | (m) |
| 2022-12-31 | $-68.30M | (m) | (m) | $54.08M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-27.11M | (m) | (m) | $19.00M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |